ReviewCurrent medicinal chemistry2025
Actinomycetes: A Source of Anticancer Metabolites.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Diversity and Ecological Origins of Anti-MRSA Metabolites fromAntibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbes in general, actinomycetes in particular, produce a wide range of antibiotics with various biological activities such as anticancer, antimicrobial, anti-inflammatory, antituberculosis and enzyme inhibition. Actinomycetes are filamentous gram-positive bacteria found in both terrestrial and marine environments. Currently, antibiotics such as Rifamycin, Tetracycline, Kanamycin, Neomycin, Streptomycin and Clavulanic acid derived from actinobacteria are highly useful in the medical field. Out of these biological activities, we need to explore the anticancer activity of various compounds isolated from different actinomycetes since cancer is a deadly disease and it is very common now a day. There are no proper medications for cancer treatment to date. The identification of a drug candidate for cancer treatment will be a striking and lifesaving achievement. Many more research activities must be done in this field. Many molecules have been used as chemotherapeutic agents reported from actinobacteria used for cancer treatment. In this review, various anticancer compounds isolated from the crude extracts of different marine and soil actinomycetes have been reported from 2000-2022. The aim of this review is to summarize and consolidate the anticancer and cytotoxic compounds isolated from the actinomycetes (from different locations) to encourage the scientific community to concentrate more on this field, which will serve good for mankind.
Indexed as
Identifiers
39716804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.